Metastatic Kidney Cancer Clinical Trial
Official title:
Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer
Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney
cancer.
Collection of additional blood tubes during routine blood tests for patient follow-up, to
evaluate the plasma concentration of Sunitinib and its active metabolite desethyl-Sunitinib
(DES)
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
| Not yet recruiting |
NCT04889495 -
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
|
||
| Terminated |
NCT01336231 -
Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer
|
N/A | |
| Recruiting |
NCT06180460 -
CALM: Managing Distress in Malignant Brain Cancer
|
N/A | |
| Completed |
NCT02035358 -
Immunotherapy Study for Metastatic Renal Cell Cancer
|
Phase 1 | |
| Completed |
NCT00328861 -
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
|
Phase 2 | |
| Recruiting |
NCT05796973 -
Measuring Oncological Value of Exercise and Statin
|
Phase 3 | |
| Withdrawn |
NCT01355562 -
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04385654 -
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT00942058 -
Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer
|
N/A | |
| Withdrawn |
NCT03189186 -
Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
|
Phase 1 | |
| Active, not recruiting |
NCT03280667 -
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06364631 -
CARE1 Pragmatic Clinical Trial
|
Phase 3 |